Improved Insulin Sensitivity in 80 Nondiabetic Patients With MDD After Clinical Remission in a Double-Blind, Randomized Trial of Amitriptyline and Paroxetine
J Clin Psychiatry 2006;67(12):1856-1861
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: There is substantial evidence
that depression constitutes a risk factor for type 2
diabetes mellitus. A recent study has shown that
high salivary cortisol levels are associated with
decreased insulin sensitivity in unmedicated, depressed patients. Further, antidepressive
treatment might have differential effects on
hypothalamus-pituitary-adrenal (HPA) system activity.
Therefore, the aim of the present study was to
examine whether insulin sensitivity improves during
antidepressive treatment in depressed patients
with declining HPA system activity.
Method: Eighty inpatients with an episode
of major depressive disorder (DSM-IV criteria)
were treated in a double-blind, randomized
protocol with either amitriptyline or paroxetine over a
period of 5 weeks. After 6 drug-free days, an oral glucose tolerance test was performed on day
1 and again 35 days after antidepressive
treatment. For quantification of free cortisol levels,
saliva was obtained daily at 8:00 a.m. during weeks
-1 (washout) and 5. The study was conducted from May 2005 to December 2005.
Results: The insulin sensitivity
indexMatsuda increased in only those patients who
remitted from major depressive disorder as a result
of treatment with either antidepressant (F = 7.0, df
= 1,74; p < .01), while correcting for body
mass index. Further, cortisol concentrations declined
in remitters and responders to amitriptyline (F =
2.1, df = 1,70; p < .05), but not in any other subgroup.
Conclusion: Successful antidepressive
treatment with either a selective serotonin
reuptake inhibitor or a tricyclic substance increases
the sensitivity to insulin in nondiabetic
depressed patients. The herein presented longitudinal
data do not exclude the HPA system as a major contributor to insulin resistance in depressed
patients, but underscore the assumption of additional